Table 6. One-way sensitivity analysis of the net monetary benefit of strategy ‘TRS & GRS optimized’.

	Net monetary benefit (€)
Base case	379 786€
Cost of a fatal CHD event (base case 2 417€; ±15%)
2 055€	+6€
2 780€	-6€
Cost of a non-fatal CHD event (base case 19 860€; ±15%)
16 881€	+180€
22 839€	-179€
Annual statin costs (base case 53€; ±25%)
40€	+16€
66€	-15€
Annual monitoring costs in primary prevention (base case 173€; ±25%)
130€	+56€
217€	-49€
Annual secondary prevention costs (base case: 451€; ±25%)
339€	+27€
564€	-27€
Disutility due to a non-fatal CHD event (base case -0.147 QALY; ±25%)
-0.110 QALY	+111€
-0.184 QALY	-111€
Probability of death in case of a CHD event (base case 22%; ±25%)
16%	+639€
27%	-629€
Risk reduction if statin treatment (base case 27%; ±25%)
20%	-254€
34%	+281€
Cost of TRS (base case 173€; ±25%)
130€	+18€
217€	-15€
Cost of GRS (base case 200€; ±50%)
100€	+5€
300€	-2€